Publications

Plasmodium sporozoites require the protein B9 to invade hepatocytes

02 February 2023

O. Silvie’s team has identified a Plasmodium protein that is essential for the infection of hepatocytes during malaria. This protein, called B9, could constitute a new vaccine target.

Publications

T-independent responses to polysaccharides in humans mobilize marginal zone B cells prediversified against gut bacterial antigens

01 February 2023

A novel CIMI collaboration underlines the key role played by the immune/microbiota interface in the pre-education of the human antibody repertoire.

The news of the cimi

Team’s FRM 2022 – G Gorochov

10 January 2023

Guy Gorochov’s team has been awarded the Equipe FRM 2022 label for the project «Study and manipulation of host-microbiota mutualism regulated by immunoglobulin A»

Publications Logo Cimi Paris

“Lower disease activity but higher risk of severe COVID- 19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α”

17 August 2022
Publications Logo Cimi Paris

Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage

07 July 2022

Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage.

The news of the cimi Logo Cimi Paris

Vaccine responses against SARS-CoV-2 variants examined in people with lupus

08 October 2021

The majority of people with systemic lupus erythematosus (SLE) who respond to messenger (m)RNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.

Publications Logo Cimi Paris

A personalized precision medicine approach is needed to treat Covid-19 as more than one type of “Cytokine storm” is induced by SARS-CoV-2

07 October 2021

The severe form of Covid-19 is known to be associated with the excessive elevation of many cytokines, a condition termed “cytokine storm”. Therapy with biological agents intended to block these cytokines, for example anti-interleukin-6 or anti-interleukin-1 antibodies, was already tried, albeit with a limited success.